Roche acquires innovatis AG to complement its product portfolio in the rapidly growing area of cellular analytics

03-17-2009: Roche announced that it has signed a definite agreement under which Roche will acquire 100% of innovatis. innovatis is a provider of automated cell analysis solutions, especially focussing on cell counting, viability testing, and cell function analysis in research, as well as bioproduction. The purchase price for this transaction is 15 million Euros.

"This acquisition is a further step in our strategy to strengthen our position as a complete solution provider in the cell analysis research market,” said Dr. Jürgen Schwiezer, CEO Division Roche Diagnostics. “Innovatis’ technology will complement the existing Roche cell analysis portfolio and is synergistic to the xCELLigence technology launched in 2008.”

Innovatis will become a fully-integrated part of Roche Applied Science, a global business area of the Diagnostic Division of Roche. The company will continue to develop and market products for cell analysis through Roche Applied Science’s extensive worldwide network. The transaction is expected to be completed within the next few weeks, subject to shareholder approval and regulatory clearance.

Facts, background information, dossiers
More about Roche Diagnostics
More about innovatis
More about Roche
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE